LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

MannKind Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

4.52 11.33

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.06

Max

4.61

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-12M

668K

Pardavimai

-1.8M

77M

P/E

Sektoriaus vid.

34.636

35.473

Pelno marža

0.873

Darbuotojai

403

EBITDA

8.3M

27M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+141.79% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-22M

1.2B

Ankstesnė atidarymo kaina

-6.81

Ankstesnė uždarymo kaina

4.52

Naujienos nuotaikos

By Acuity

50%

50%

181 / 372 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-26 23:56; UTC

Uždarbis

WiseTech Lifts Dividend as Its Annual Profit Rises 30% -- Update

2025-08-26 23:48; UTC

Uždarbis

Woolworths Annual Profit Falls, Cuts Dividend

2025-08-26 23:41; UTC

Uždarbis

WiseTech Lifts Dividend as Its Annual Profit Rises 30%

2025-08-26 23:58; UTC

Uždarbis

China Resources Land: Real-Estate Sector Faces Structural Challenges, but Homebuying Demand Gradually Returning >1109.HK

2025-08-26 23:57; UTC

Uždarbis

China Resources Land: 1H Results Buoyed by Investment Property & Asset Management Business >1109.HK

2025-08-26 23:55; UTC

Uždarbis

China Resources Land 1H Net CNY11.88B Vs. Net CNY10.22B >1109.HK

2025-08-26 23:55; UTC

Uždarbis

China Resources Land 1H Rev CNY94.92B Vs. CNY79.19B >1109.HK

2025-08-26 23:48; UTC

Uždarbis

Karoon Energy Interim Dividend 2.4 Australian Cents/Security

2025-08-26 23:47; UTC

Uždarbis

Karoon Energy 1H Underlying Net Profit US$45 Million, Down 61% on Year

2025-08-26 23:47; UTC

Uždarbis

Karoon Energy 1H Revenue US$308.3 Million, Down 25% on Year

2025-08-26 23:47; UTC

Uždarbis

Karoon Energy 1H Net Profit US$71 Million, Up 15% on Year

2025-08-26 23:46; UTC

Rinkos pokalbiai

Nikkei May Trade in Range Amid US Tariff Uncertainty -- Market Talk

2025-08-26 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments -- Market Talk

2025-08-26 23:35; UTC

Uždarbis

Karoon Energy Expects Expenditure of US$80 Million-US$90 Million Over 2030-2034

2025-08-26 23:35; UTC

Uždarbis

Karoon Energy Expects Expenditure of US$55 Million-US$65 Million for Projects in 2026

2025-08-26 23:34; UTC

Uždarbis

Karoon Energy: Baúna Revitalization, Life Extension Projects Initiated

2025-08-26 23:34; UTC

Uždarbis

Karoon Energy: Baúna Project Economic Field Life Extends to 2039

2025-08-26 23:33; UTC

Uždarbis

Karoon Energy Raises Baúna Project 2P Reserves by 13.7 Million Bbls

2025-08-26 23:23; UTC

Uždarbis

WiseTech: FY25 Ebitda Margin Exit Run Rate 52%>WTC.AU

2025-08-26 23:22; UTC

Uždarbis

WiseTech: New CargoWise Commercial Model Ready for Rollout>WTC.AU

2025-08-26 23:21; UTC

Uždarbis

WiseTech Says Integration of e2open Is on Track>WTC.AU

2025-08-26 23:14; UTC

Uždarbis

WiseTech Expects FY26 Ebitda Margin of 40-41%>WTC.AU

2025-08-26 23:13; UTC

Uždarbis

WiseTech Expects FY26 Ebitda Growth of 44-53%>WTC.AU

2025-08-26 23:13; UTC

Uždarbis

WiseTech Expects FY26 Ebitda of $550M-$585M>WTC.AU

2025-08-26 23:13; UTC

Uždarbis

WiseTech Expects FY26 Revenue Growth of 79-85%>WTC.AU

2025-08-26 23:12; UTC

Uždarbis

WiseTech Expects FY26 Revenue of $1.39B-$1.44B>WTC.AU

2025-08-26 23:11; UTC

Uždarbis

WiseTech FY Ebitda Margin Ex-e2open Costs 53%>WTC.AU

2025-08-26 23:11; UTC

Uždarbis

WiseTech FY Ebitda Margin 49% Vs. 48%>WTC.AU

2025-08-26 23:10; UTC

Uždarbis

WiseTech FY Ebitda $381.6M Vs. $325.0M>WTC.AU

2025-08-26 23:09; UTC

Uždarbis

WiseTech Global Declares Dividend of $0.077 >WTC.AU

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

141.79% į viršų

12 mėnesių prognozė

Vidutinis 9.43 USD  141.79%

Aukščiausias 12 USD

Žemiausias 7 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.079 / 4.323Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

181 / 372 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.